237 related articles for article (PubMed ID: 35348009)
1. Two Pyroptosis-Related Subtypes with Distinct Immune Microenvironment Characteristics and a Novel Signature for Predicting Immunotherapy Response and Prognosis in Uveal Melanoma.
Lei S; Li H
Curr Eye Res; 2022 Jun; 47(6):930-943. PubMed ID: 35348009
[TBL] [Abstract][Full Text] [Related]
2. Identification of survival-related genes and a novel gene-based prognostic signature involving the tumor microenvironment of uveal melanoma.
Lei S; Zhang Y
Int Immunopharmacol; 2021 Jul; 96():107816. PubMed ID: 34162166
[TBL] [Abstract][Full Text] [Related]
3. Construction and validation of a pyroptosis-related gene signature associated with the tumor microenvironment in uveal melanoma.
Zhang F; Deng Y; Wang D; Wang S
Sci Rep; 2022 Jan; 12(1):1640. PubMed ID: 35102195
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive genomic signature of pyroptosis-related genes and relevant characterization in hepatocellular carcinoma.
Wang S; Gao S; Shan L; Qian X; Luan J; Lv X
PeerJ; 2023; 11():e14691. PubMed ID: 36650832
[TBL] [Abstract][Full Text] [Related]
5. Construction and comprehensive analysis of a novel prognostic signature associated with pyroptosis molecular subtypes in patients with pancreatic adenocarcinoma.
Huang Q; Peng X; Li Q; Zhu J; Xue J; Jiang H
Front Immunol; 2023; 14():1111494. PubMed ID: 36817451
[TBL] [Abstract][Full Text] [Related]
6. The prognostic landscape of adaptive immune resistance signatures and infiltrating immune cells in the tumor microenvironment of uveal melanoma.
Wang Y; Xu Y; Dai X; Lin X; Shan Y; Ye J
Exp Eye Res; 2020 Jul; 196():108069. PubMed ID: 32439398
[TBL] [Abstract][Full Text] [Related]
7. Immunogenic profiling of metastatic uveal melanoma discerns a potential signature related to prognosis.
Wang J; Liu M; Sun J; Zhang Z
J Cancer Res Clin Oncol; 2024 Jan; 150(1):23. PubMed ID: 38246894
[TBL] [Abstract][Full Text] [Related]
8. A risk model based on pyroptosis subtypes predicts tumor immune microenvironment and guides chemotherapy and immunotherapy in bladder cancer.
Wu T; Li S; Yu C; Wu Y; Long H
Sci Rep; 2022 Dec; 12(1):21467. PubMed ID: 36509838
[TBL] [Abstract][Full Text] [Related]
9.
Meng Z; Chen Y; Wu W; Yan B; Zhang L; Chen H; Meng Y; Liang Y; Yao X; Luo J
Front Immunol; 2022; 13():754645. PubMed ID: 35281030
[TBL] [Abstract][Full Text] [Related]
10. A Comprehensive Prognostic and Immunological Analysis of a Six-Gene Signature Associated With Glycolysis and Immune Response in Uveal Melanoma.
Liu J; Lu J; Li W
Front Immunol; 2021; 12():738068. PubMed ID: 34630418
[TBL] [Abstract][Full Text] [Related]
11. Tumor subtypes and signature model construction based on chromatin regulators for better prediction of prognosis in uveal melanoma.
Li Y; Xiong C; Wu LL; Zhang BY; Wu S; Chen YF; Xu QH; Liao HF
Pathol Oncol Res; 2023; 29():1610980. PubMed ID: 37362244
[No Abstract] [Full Text] [Related]
12. Development and validation of immunogenic cell death-related signature for predicting the prognosis and immune landscape of uveal melanoma.
Hu Y; Cai J; Ye M; Mou Q; Zhao B; Sun Q; Lou X; Zhang H; Zhao Y
Front Immunol; 2022; 13():1037128. PubMed ID: 36466923
[TBL] [Abstract][Full Text] [Related]
13. Multiomics characterization of pyroptosis in the tumor microenvironment and therapeutic relevance in metastatic melanoma.
Chen W; He Y; Zhou G; Chen X; Ye Y; Zhang G; Liu H
BMC Med; 2024 Jan; 22(1):24. PubMed ID: 38229080
[TBL] [Abstract][Full Text] [Related]
14. Landscape of Infiltrated Immune Cell Characterization in Uveal Melanoma to Improve Immune Checkpoint Blockade Therapy.
Lv X; Ding M; Liu Y
Front Immunol; 2022; 13():848455. PubMed ID: 35309331
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
[TBL] [Abstract][Full Text] [Related]
16. Identification of Survival-Related Metabolic Genes and a Novel Gene Signature Predicting the Overall Survival for Patients with Uveal Melanoma.
Guo X; Yu X; Li F; Xia Q; Ren H; Chen Z; Xing Y
Ophthalmic Res; 2022; 65(5):516-528. PubMed ID: 35390784
[TBL] [Abstract][Full Text] [Related]
17. N
Liu Z; Li S; Huang S; Wang T; Liu Z
Front Oncol; 2021; 11():704543. PubMed ID: 34395276
[TBL] [Abstract][Full Text] [Related]
18. Pyroptosis-Related Gene Signature Predicts Prognosis and Indicates Immune Microenvironment Infiltration in Glioma.
Zhang Y; Zhang C; Yang Y; Wang G; Wang Z; Liu J; Zhang L; Yu Y
Front Cell Dev Biol; 2022; 10():862493. PubMed ID: 35547808
[No Abstract] [Full Text] [Related]
19. The Dark Side of Pyroptosis of Diffuse Large B-Cell Lymphoma in B-Cell Non-Hodgkin Lymphoma: Mediating the Specific Inflammatory Microenvironment.
Wang W; Xu SW; Teng Y; Zhu M; Guo QY; Wang YW; Mao XL; Li SW; Luo WD
Front Cell Dev Biol; 2021; 9():779123. PubMed ID: 34805183
[No Abstract] [Full Text] [Related]
20. Role of immune checkpoint inhibitors and novel immunotherapies in uveal melanoma.
Jindal V
Chin Clin Oncol; 2018 Feb; 7(1):8. PubMed ID: 29486567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
